Skip to main content

Table 4 Total healthcare costs (excluding treatment acquisition) for bedaquiline plus BR versus BR in the analyzed countries

From: Health outcomes of bedaquiline in the treatment of multidrug-resistant tuberculosis in selected high burden countries

 

Estonia

Russia

South Africa

Peru

China

Philippines

India

Cohort

 Populationa, cases (n)

38

6,537

6,494

564

826

11

20,763

Hospitalization costs (at 100% hospitalization), US$ totalb/per patientc

 Bedaquiline + BR

2,515,318/66,193

400,933,524/61,333

85,584,735/13,179

8,505,448/15,080

7,792,452/9,434

35,660/3,242

4,892,107/236

 BR only

3,780,243/99,480

596,419,985/91,238

129,930,717/20,008

12,699,038/22,516

11,177,776/13,532

52,799/4,800

7,376,327/355

Outpatient care, US$ totalb/per patientc

 Bedaquiline + BR

23,858/628

1,716,115/263

1,221,043/188

47,999/85

77,975/94

394/36

1,740,459/84

 BR only

17,667/465

1,109,759/170

1,144 148/20,008

31,283/55

72,985/88

249/23

1,979,948/95

Monitoring costs, US$ totalb/per patientc

 Bedaquiline + BR

66,887/1,760

11,449,710/1,752

7,778,834/1,198

721,800/1,280

930,012/1,126

9,182/835

15,202,670/732

 BR only

69,860/1,838

10,165,718/1,555

6,808,367/1,048

682,575/1,210

1,019,445/1,234

8,989/817

16,650,529/802

Total healthcare costs (excluding treatment acquisition costs), US$ totalb/per patientc

 Bedaquiline + BR

2,606,062/68,581

414,099,348/63,347

94,584,612/14,565

9,275,248/16,445

8,800,439/10,654

45,236/4,112

21,835,236/1,052

 BR only

3,867,769/101,783

607,695,462/92,962

137,883,232/21,232

13,412,896/23,782

12,270,205/14,855

62,037/5,640

26,006,804/1,253

 Incremental health care cost-savings (excluding acquisition costs) (bedaquiline + BR vs. BR), US$ totalb/per patientc

1,261,707/33,202

193,596,114/29,615

43,298,620/6,667

4,137,648/7,337

3,469,766/4,201

16,801/1,528

4,171,568/201

  1. BR background regimen, TB tuberculosis, US United States
  2. aPopulation cohort: Russia, China, Philippines: New lab-confirmed MDR-TB cases in 2012 [31]; South Africa: Total number of patients started on MDR-TB treatment in 2012 [31]; Estonia, Peru: laboratory-confirmed MDR-TB cases in 2012 [31]; India: Total number of patients started on MDR-TB treatment in 2013 [2]; bTotal costs (inflated to US$ 2013) reflect costs for the entire cohort of patients; cper patient costs (inflated to US$ 2013) are calculated by dividing the total costs by the population cases (n)